Drug
Nyx 783
Nyx 783: highest development phase Phase 2/3, developed by Aptinyx. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Aptinyx
Trials
| Drug | Phase | Indication |
|---|---|---|
| NYX-783 NCT05181995 | Phase 2/3 | PTSD |
| NYX-783 NCT04044664 | Phase 2 | Post-Traumatic Stress Disorder |
Latest
No recent events.
Follow Nyx 783 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.